NRX Pharma rises on start to late-stage study of bipolar disorder drug

NRX Pharmaceuticals

03/01/2023 12:26

** Drug developer NRX Pharmaceuticals Inc's  NRXP.O  shares
up 16.2% at $1.29 premarket
    ** Co initiates late-stage study of investigational drug for
patients with severe bipolar depression and acute suicidal
behavior
    ** First trial site has been contracted and first dosing of
patients is expected in early 2023 - NRXP
    ** Drug holds breakthrough therapy tag from the U.S. FDA
    ** Last year, stock had declined 76.8% YTD
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))